194 related articles for article (PubMed ID: 27722772)
1. Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients.
Shimoura H; Tanaka H; Matsumoto K; Mochizuki Y; Hatani Y; Hatazawa K; Matsuzoe H; Ooka J; Sano H; Sawa T; Motoji Y; Ryo-Koriyama K; Hirata KI
Heart Vessels; 2017 May; 32(5):584-590. PubMed ID: 27722772
[TBL] [Abstract][Full Text] [Related]
2. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
[TBL] [Abstract][Full Text] [Related]
3. Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study.
Sezai A; Soma M; Hata M; Yoshitake I; Unosawa S; Wakui S; Shiono M
Ann Thorac Cardiovasc Surg; 2011; 17(5):487-93. PubMed ID: 21881353
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
Tsutamoto T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
Hypertens Res; 2010 Feb; 33(2):118-22. PubMed ID: 19927151
[TBL] [Abstract][Full Text] [Related]
5. Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch.
Benedetto U; Melina G; Refice S; di Bartolomeo R; Roscitano A; Angeloni E; Sinatra R
Ann Thorac Surg; 2010 Dec; 90(6):1899-903; discussion 1903. PubMed ID: 21095333
[TBL] [Abstract][Full Text] [Related]
6. Influence of Left Ventricular Ejection Fraction on the Effects of Supplemental Use of Angiotensin Receptor Blocker Olmesartan in Hypertensive Patients With Heart Failure.
Miura M; Sakata Y; Miyata S; Shiba N; Takahashi J; Nochioka K; Takada T; Saga C; Shinozaki T; Sugi M; Nakagawa M; Sekiguchi N; Komaru T; Kato A; Fukuchi M; Nozaki E; Hiramoto T; Inoue K; Goto T; Ohe M; Tamaki K; Ibayashi S; Ishide N; Maruyama Y; Tsuji I; Shimokawa H;
Circ J; 2016 Sep; 80(10):2155-64. PubMed ID: 27628221
[TBL] [Abstract][Full Text] [Related]
7. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.
Jones MR; Sealey JE; Laragh JH
Am J Hypertens; 2007 Aug; 20(8):907-16. PubMed ID: 17679042
[TBL] [Abstract][Full Text] [Related]
8. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.
Agata J; Ura N; Yoshida H; Shinshi Y; Sasaki H; Hyakkoku M; Taniguchi S; Shimamoto K
Hypertens Res; 2006 Nov; 29(11):865-74. PubMed ID: 17345786
[TBL] [Abstract][Full Text] [Related]
9. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
Ovchinnikov AG; Serbul VM; Ageev FT
Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
[TBL] [Abstract][Full Text] [Related]
10. Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function.
Albayrak S; Ordu S; Ozhan H; Yazici M; Aydin M; Alemdar R; Kaya A
Blood Press; 2009; 18(4):187-91. PubMed ID: 19521888
[TBL] [Abstract][Full Text] [Related]
11. Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2.
Kaiqiang Ji ; Minakawa M; Fukui K; Suzuki Y; Fukuda I
Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):103-11. PubMed ID: 19171689
[TBL] [Abstract][Full Text] [Related]
12. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Maisaidi M; Zanchetti A
Blood Press; 2006; 15(2):107-15. PubMed ID: 16754274
[TBL] [Abstract][Full Text] [Related]
13. Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial--rationale and design.
Sakata Y; Nochioka K; Miura M; Takada T; Tadaki S; Miyata S; Shiba N; Shimokawa H
J Cardiol; 2013 Jul; 62(1):31-6. PubMed ID: 23769179
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.
Yasunari K; Maeda K; Watanabe T; Nakamura M; Yoshikawa J; Asada A
J Am Coll Cardiol; 2004 Jun; 43(11):2116-23. PubMed ID: 15172423
[TBL] [Abstract][Full Text] [Related]
15. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
[TBL] [Abstract][Full Text] [Related]
16. Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Krauser DG; Devereux RB
Herz; 2006 Jun; 31(4):305-16. PubMed ID: 16810470
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.
Goette A; Schön N; Kirchhof P; Breithardt G; Fetsch T; Häusler KG; Klein HU; Steinbeck G; Wegscheider K; Meinertz T
Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):43-51. PubMed ID: 22157519
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Efficacy and Safety of Azilsartan and Olmesartan in Patients With Essential Hypertension.
Shiga Y; Miura SI; Motozato K; Norimatsu K; Yano M; Hitaka Y; Adachi S; Kuwano T; Inoue K; Inoue A; Fujisawa K; Shirotani T; Kusumoto T; Ideishi M; Saku K
Int Heart J; 2017 May; 58(3):416-421. PubMed ID: 28496022
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
Hawkins NM; Wang D; McMurray JJ; Pfeffer MA; Swedberg K; Granger CB; Yusuf S; Pocock SJ; Ostergren J; Michelson EL; Dunn FG;
Heart; 2007 Jan; 93(1):59-64. PubMed ID: 16952975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
